(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
NASA's make-or-break moon shot - 2Reactions as Artemis II astronauts lift off on historic lunar mission
- 3The 15 Most Motivating TED Discusses All Time
- 4Spain and Catholic Church agree to compensate sex abuse victims
- 5Artemis II astronauts race to set a new distance record from Earth and behold the moon's far side
- Figure out How to Get the Most Familiar Drive for Seniors in SUVs
- 'Wuthering Heights' trailer features Margot Robbie and Jacob Elordi in a steamy forbidden romance
- The Best Computer games for Multiplayer Fun
- A Manual for Pick Great Lawful Discussion Administrations For New businesses In 2024
- British-Egyptian dissident apologises for tweets as Tories push for UK deportation
- How a cocktail of rogue storms and climate chaos unleashed deadly flooding across Asia
- Daily Briefing: A bad flu season gets worse
- The risk of falling space junk hitting airplanes is on the rise, experts warn
- What to know about voluntary chocolate recall
